Drug intelligence / Profile preview

NIPEP-PAH

Development stage: Preclinical
Lead developer: Nano Intelligent Biomedical Engineering
Modality: Peptides

Overview

NIPEP-PAH is a peptide-based therapeutic candidate being developed by Nano Intelligent Biomedical Engineering Corporation (NIBEC) for the treatment of pulmonary arterial hypertension (PAH). The drug is part of NIBEC's proprietary NIPEP (Nano-Intelligent Peptide) platform, which focuses on the development of engineered peptides for regenerative and targeted therapies. NIPEP-PAH is designed to address the underlying vascular remodeling and high blood pressure in the pulmonary arteries associated with PAH. As of early 2024, the program is in the preclinical stage of development, and its specific molecular target has not been publicly disclosed by the developer.

Other names: Pulmonary Arterial Hypertension Treatment

Beyond the preview

Go deeper on NIPEP-PAH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIPEP-PAH.

Explore the full profile